
|Videos|May 13, 2014
Combining Immunotherapies
Author(s)Jedd D. Wolchok, MD, PhD
Jedd D. Wolchok, MD, PhD, from Memorial Sloan Kettering Cancer Center, discusses ongoing research regarding combinations of immunotherapies.
Advertisement
Clinical Pearls
Jedd D. Wolchok, MD, PhD, chief, Melanoma and Immunotherapeutics Service, Lloyd J. Old Chair for Clinical Investigation, Memorial Sloan Kettering Cancer Center, discusses ongoing research regarding combinations of immunotherapies.
- Aphase III study led by MSKaims to compare nivolumab, ipilimumab, and the combination of the drugs in newly diagnosed patients with advanced melanoma.
- There remains a need to determine the benefits of concurrent combination therapies versus sequenced therapies.
Advertisement
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
Dr Cloughesy on Extended Follow-Up Data for Vorasidenib in IDH1/2 Mutant Glioma
2
Bispecific ADC Iza-Bren Extends Survival in Advanced TNBC
3
ASCO 2026 GU Cancer Highlights: Beyond the LBAs
4
FDA Grants Priority Review to Giredestrant for ER+/HER2- Breast Cancer
5



































